论文信息 - 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

[1] transcript Open Library. European Regions , 2020 .

[2] Deepak L. Bhatt,et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[3] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[4] S. Grundy,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[5] C. Ballantyne,et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol , 2019, The New England journal of medicine.

[6] P. Libby,et al. Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[7] John Fuller,et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials , 2019, The Lancet.

[8] Deepak L. Bhatt,et al. Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease , 2019, JAMA.

[9] J. Manson,et al. Marine n‐3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer , 2019, The New England journal of medicine.

[10] M. Basha,et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia , 2019, Journal of the Practice of Cardiovascular Sciences.

[11] A. Keech,et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[12] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[13] J. Pell,et al. The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort. , 2018, The Lancet. Public health.

[14] P. Libby,et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study , 2018, American heart journal.

[15] F. Song,et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. , 2018, The Cochrane database of systematic reviews.

[16] J Wouter Jukema,et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[17] L. Räber,et al. Design of the randomized, placebo‐controlled evolocumab for early reduction of LDL‐cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial , 2018, Clinical cardiology.

[18] M. Budoff,et al. Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: The Multi-Ethnic Study of Atherosclerosis (MESA). , 2018, Journal of cardiovascular computed tomography.

[19] D. Mozaffarian,et al. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study , 2018, The Lancet.

[20] R. Collins,et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[21] R. Collins,et al. Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus , 2018, The New England journal of medicine.

[22] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[23] Lawrence A Leiter,et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. , 2018, Atherosclerosis.

[24] D. Mozaffarian,et al. Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: Rationale and design of the STRENGTH trial , 2018, Clinical cardiology.

[25] R. Collins,et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase , 2018, Yearbook of Paediatric Endocrinology.

[26] L. Tokgozoglu,et al. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. , 2018, Journal of the American College of Cardiology.

[27] Dan J Stein,et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, Lancet.

[28] J. Witztum,et al. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. , 2018, Journal of clinical lipidology.

[29] V. Fuster,et al. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans , 2018, European heart journal cardiovascular Imaging.

[30] B. Lewis,et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER , 2018, Circulation.

[31] P. Barter,et al. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial , 2018, Circulation.

[32] E. Rimm,et al. Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis , 2018, The Lancet. Public health.

[33] J. Borén,et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an "FCS score". , 2018, Atherosclerosis.

[34] E. Manzato,et al. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper , 2018, Pharmacological research.

[35] Jennifer S. Lin,et al. Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[36] H. Boeing,et al. Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis[S] , 2018, Journal of Lipid Research.

[37] N. Cook,et al. Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. , 2018, Journal of the American College of Cardiology.

[38] James R. Staley,et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis , 2018, JAMA cardiology.

[39] F. Kronenberg,et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. , 2018, Clinical chemistry.

[40] W. Willett,et al. Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance , 2018, British Medical Journal.

[41] J. Martínez,et al. Retraction and Republication: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med 2013;368:1279-90. , 2018, The New England journal of medicine.

[42] Ž. Reiner. Treatment of children with homozygous familial hypercholesterolaemia , 2018, European Journal of Preventive Cardiology.

[43] Jian‐Jun Li,et al. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A systematic review and meta‐analysis , 2018, Diabetes, obesity & metabolism.

[44] C. Ballantyne,et al. Bempedoic Acid (ETC-1002): A Current Review. , 2018, Cardiology clinics.

[45] Lawrence A Leiter,et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract , 2018, European heart journal.

[46] Jennifer G. Robinson,et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.

[47] William J. Astle,et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies , 2018, The Lancet.

[48] R. Giugliano,et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes Vytorin Efficacy International Trial) , 2018, Circulation.

[49] L. Räber,et al. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials , 2018, European heart journal.

[50] Luciano de Moura Santos,et al. Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial , 2018, JAMA.

[51] R. Krasuski,et al. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes , 2018, European journal of preventive cardiology.

[52] D. Berman,et al. Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study , 2018, European heart journal.

[53] Panos Vardas,et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. , 2018, European heart journal.

[54] M. Landray,et al. Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study , 2018, Circulation. Genomic and precision medicine.

[55] C. Byrne,et al. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus , 2018, Nature Reviews Endocrinology.

[56] R. Collins,et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks , 2018, JAMA cardiology.

[57] S. Yamashita,et al. Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial , 2018, Diabetes Care.

[58] E. Guallar,et al. Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy , 2018, Circulation.

[59] A. Briggs,et al. ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies , 2017, European heart journal.

[60] J. Forman,et al. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). , 2017, The American journal of cardiology.

[61] Marc P. Bonaca,et al. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[62] P. Douville,et al. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. , 2017, Clinical biochemistry.

[63] R. Pontremoli,et al. Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[64] T. D. de Bruin,et al. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. , 2017, Journal of clinical lipidology.

[65] C. Cannon,et al. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration , 2017, European heart journal.

[66] I. Gouni-Berthold,et al. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance. , 2017, Current medicinal chemistry.

[67] M. Budoff,et al. Statin Trials, Cardiovascular Events, and Coronary Artery Calcification: Implications for a Trial-Based Approach to Statin Therapy in MESA. , 2017, JACC. Cardiovascular imaging.

[68] D. Gaudet,et al. Apolipoprotein C-III Inhibition with Volanesorsen in Patients with Hypertriglyceridemia (COMPASS): a Randomized, Double-Blind, Placebo-controlled Trial , 2017, Atherosclerosis Supplements.

[69] T. Wisløff,et al. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting , 2017, European heart journal. Cardiovascular pharmacotherapy.

[70] F. Raal,et al. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[71] L. Roth,et al. Animal models of atherosclerosis. , 2017, European journal of pharmacology.

[72] Lawrence A Leiter,et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[73] P. Clifton,et al. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[74] C. Yancy,et al. Cost-effectiveness of PCSK9 Inhibitors: Proof in the Modeling. , 2017, JAMA cardiology.

[75] H. Krumholz,et al. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial , 2017, JAMA cardiology.

[76] 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018 , 2017, Diabetes Care.

[77] A. Sposito,et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years , 2017, Diabetes Care.

[78] G. Watts,et al. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and , 2017, Circulation.

[79] N. Rocha,et al. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen , 2017, Current Atherosclerosis Reports.

[80] E. Nasli-Esfahani,et al. LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations , 2017, Journal of Diabetes & Metabolic Disorders.

[81] K. Poh,et al. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II. , 2017, Atherosclerosis.

[82] L. Räber,et al. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes , 2017, Journal of the American Heart Association.

[83] R. Giugliano,et al. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Journal of the American Heart Association.

[84] A. Keech,et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial , 2017, The Lancet.

[85] A. Zwinderman,et al. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. , 2017, Journal of the American College of Cardiology.

[86] G. Francis. Cholesterol and Heart Failure: Is There an Important Connection? , 2017, Journal of the American College of Cardiology.

[87] A. Lichtman,et al. Monocyte-Macrophages and T Cells in Atherosclerosis. , 2017, Immunity.

[88] J. Fruchart. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia , 2017, Cardiovascular Diabetology.

[89] Sidney C. Smith,et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2017, Journal of the American College of Cardiology.

[90] Peter Lindgren,et al. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease , 2017, JAMA cardiology.

[91] R. Giugliano,et al. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Circulation.

[92] F. Chen,et al. Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[93] L. Goldman,et al. Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke , 2017, Circulation.

[94] Brian A Ference,et al. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk , 2017, JAMA.

[95] L. Ferrucci,et al. Plaque Composition in the Proximal Superficial Femoral Artery and Peripheral Artery Disease Events. , 2017, JACC. Cardiovascular imaging.

[96] J. Tu,et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis , 2017, BMJ Open.

[97] P. Poirier,et al. Relation Between a Simple Lifestyle Risk Score and Established Biological Risk Factors for Cardiovascular Disease. , 2017, The American journal of cardiology.

[98] C. Held,et al. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014 , 2017, European heart journal.

[99] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[100] K. Bibbins-Domingo,et al. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial , 2017, JAMA.

[101] B. Nordestgaard,et al. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies , 2017, European heart journal.

[102] Harald H H W Schmidt,et al. Comprehensive efforts to increase adherence to statin therapy , 2017, European heart journal.

[103] A. Keech,et al. Cognitive Function in a Randomized Trial of Evolocumab , 2017, The New England journal of medicine.

[104] T. Nozue. Lipid Lowering Therapy and Circulating PCSK9 Concentration , 2017, Journal of atherosclerosis and thrombosis.

[105] N. Lundbom,et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity , 2017, Journal of internal medicine.

[106] L. Shaw,et al. Implications of Coronary Artery Calcium Testing for Treatment Decisions Among Statin Candidates According to the ACC/AHA Cholesterol Management Guidelines: A Cost-Effectiveness Analysis. , 2017, JACC. Cardiovascular imaging.

[107] S. Devaraj,et al. Underestimation of Low Density Lipoprotein-Cholesterol With the Friedewald Equation Versus a Direct Homogenous Low Density Lipoprotein-Cholesterol Assay , 2017, Laboratory medicine.

[108] D. Gaudet,et al. The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). , 2017, Atherosclerosis.

[109] D. Gaudet,et al. ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. , 2017, The New England journal of medicine.

[110] Michael Miller,et al. Dietary Fats and Cardiovascular Disease: A Presidential Advisory From the American Heart Association , 2017, Circulation.

[111] E. Stein,et al. Are the PCSK9 inhibitors the panacea of atherosclerosis treatment? , 2017, Expert review of cardiovascular therapy.

[112] A. Jaffe,et al. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. , 2017, Journal of clinical lipidology.

[113] H. Kamel,et al. Statin Adherence Is Associated With Reduced Recurrent Stroke Risk in Patients With or Without Atrial Fibrillation , 2017, Stroke.

[114] R. Collins,et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase , 2017, The Lancet.

[115] G. Backer,et al. Food supplements with red yeast rice: More regulations are needed , 2017, European journal of preventive cardiology.

[116] H. Bøtker,et al. Patients With Diabetes Without Significant Angiographic Coronary Artery Disease Have the Same Risk of Myocardial Infarction as Patients Without Diabetes in a Real-World Population Receiving Appropriate Prophylactic Treatment , 2017, Diabetes Care.

[117] C. Weber,et al. Therapeutic strategies for atherosclerosis and atherothrombosis: Past, present and future , 2017, Thrombosis and Haemostasis.

[118] Paul D. Martin,et al. Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label) , 2017, Circulation.

[119] M. Suhrcke,et al. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial , 2017, The Lancet.

[120] N. Stone,et al. Relation of Intensity of Statin Therapy and Outcomes After Transcatheter Aortic Valve Replacement. , 2017, The American journal of cardiology.

[121] Richard G. Lee,et al. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides , 2017, The New England journal of medicine.

[122] C. Granger,et al. Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease , 2017, The New England journal of medicine.

[123] A. Vyas,et al. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States , 2017, Journal of medical economics.

[124] D. Demicco,et al. Early, intensive statin treatment reduces ‘hard’ cardiovascular outcomes after acute coronary syndrome , 2017, European journal of preventive cardiology.

[125] D. Mark,et al. Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes Vytorin Efficacy International Trial) , 2017, Circulation. Cardiovascular quality and outcomes.

[126] John P. Overington,et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. , 2017, The Cochrane database of systematic reviews.

[127] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[128] N. Hagiwara,et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial , 2017, European heart journal.

[129] Manfred S. Green,et al. Usefulness of Non-High-Density Lipoprotein Cholesterol as a Predictor of Cardiovascular Disease Mortality in Men in 22-Year Follow-Up. , 2017, The American journal of cardiology.

[130] Björn Eliasson,et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes , 2017, The New England journal of medicine.

[131] Lawrence A Leiter,et al. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes , 2017, JAMA cardiology.

[132] J. Danesh,et al. ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. , 2017, Journal of the American College of Cardiology.

[133] R. Hegele,et al. Complexity of mechanisms among human proprotein convertase subtilisin–kexin type 9 variants , 2017, Current opinion in lipidology.

[134] A. Marais,et al. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder , 2017, Current opinion in endocrinology, diabetes, and obesity.

[135] P. Ridker,et al. Lipid‐Reduction Variability and Antidrug‐Antibody Formation with Bococizumab , 2017, The New England journal of medicine.

[136] Lawrence A Leiter,et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol , 2017, The New England journal of medicine.

[137] P. Ponikowski,et al. Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients , 2017, The New England journal of medicine.

[138] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[139] Deepak L. Bhatt,et al. Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial , 2017, Clinical cardiology.

[140] M. Bourbon,et al. Lysosomal acid lipase deficiency: A hidden disease among cohorts of familial hypercholesterolemia? , 2017, Journal of clinical lipidology.

[141] R. Giugliano,et al. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. , 2017, Journal of the American College of Cardiology.

[142] S. Tsimikas. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. , 2017, Journal of the American College of Cardiology.

[143] Jennifer G. Robinson,et al. Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials. , 2017, Journal of the American College of Cardiology.

[144] B. Burnand,et al. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials , 2017, PloS one.

[145] S. de Servi,et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis , 2017, PloS one.

[146] G. Lippi,et al. Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[147] Heather B. Blunt,et al. Weight Loss Interventions in Older Adults with Obesity: A Systematic Review of Randomized Controlled Trials Since 2005 , 2017, Journal of the American Geriatrics Society.

[148] J. Greving,et al. Cost‐Effectiveness of Intensifying Lipid‐Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients , 2017, Journal of the American Heart Association.

[149] Hynek Pikhart,et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study , 2017, The lancet. Diabetes & endocrinology.

[150] P. Zimmet. Diabetes and its drivers: the largest epidemic in human history? , 2017, Clinical Diabetes and Endocrinology.

[151] J. Kastelein,et al. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. , 2017, Cardiovascular diagnosis and therapy.

[152] A. Kengne,et al. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: A systematic review and meta-analysis of randomized controlled trials. , 2017, International journal of cardiology.

[153] U. Laufs,et al. Pleiotropic Effects of Statins on the Cardiovascular System , 2017, Circulation research.

[154] B. Bettencourt,et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 , 2017, The New England journal of medicine.

[155] J. Zamorano,et al. European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk , 2016, European heart journal.

[156] G. Grosso,et al. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal? , 2017, Critical reviews in food science and nutrition.

[157] F. Bernini,et al. Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[158] A. Khera,et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey , 2017, JAMA cardiology.

[159] Jennifer G. Robinson,et al. Determining When to Add Nonstatin Therapy: A Quantitative Approach. , 2016, Journal of the American College of Cardiology.

[160] A. Neumann,et al. The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program , 2016, The European Journal of Health Economics.

[161] J. Spertus,et al. Association Between Cardiac Rehabilitation Participation and Health Status Outcomes After Acute Myocardial Infarction. , 2016, JAMA cardiology.

[162] Szilard Voros,et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. , 2016, The New England journal of medicine.

[163] O. Franco,et al. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis. , 2016, JAMA.

[164] Peter Sandercock,et al. Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[165] S. Crooke,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[166] M. Chedid,et al. DIETARY MANAGEMENT FOR DYSLIPIDEMIA IN LIVER TRANSPLANT RECIPIENTS , 2016, Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery.

[167] B. Nordestgaard,et al. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[168] A. Hoes,et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. , 2016, European heart journal.

[169] T. McCormack,et al. Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date , 2016, International journal of clinical practice.

[170] J. Borén,et al. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity , 2016, Current opinion in lipidology.

[171] T. Lobstein,et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta‐analysis , 2016, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[172] Brian A Ference,et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.

[173] G. Targher. Non-alcoholic fatty liver disease as driving force in coronary heart disease? , 2016, Gut.

[174] H. Nathoe,et al. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease. , 2016, The American journal of cardiology.

[175] J. Borén,et al. Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease? , 2016, Current Atherosclerosis Reports.

[176] C. R. Macedo,et al. Statins for aortic valve stenosis. , 2016, The Cochrane database of systematic reviews.

[177] D. Karalis,et al. The risks of statin use in pregnancy: A systematic review. , 2016, Journal of clinical lipidology.

[178] L. Joosten,et al. Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans , 2016, Circulation.

[179] Richard G. Lee,et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. , 2016, The Journal of clinical investigation.

[180] M. Landray,et al. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. , 2016, The lancet. Diabetes & endocrinology.

[181] S. Wright,et al. Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112 , 2016, Circulation research.

[182] Sidney C. Smith,et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2016, Journal of the American College of Cardiology.

[183] D. De Bacquer,et al. Cardiovascular risk estimation in older persons: SCORE O.P. , 2016, European journal of preventive cardiology.

[184] S. de Lusignan,et al. Microvascular Disease and Risk of Cardiovascular Events Among Individuals With Diabetes : a Population-Level Cohort Study , 2016 .

[185] Biao Xu,et al. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. , 2016, Annals of internal medicine.

[186] Richard G. Lee,et al. Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes , 2016, Diabetes Care.

[187] A. Sahebkar,et al. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. , 2016, British journal of clinical pharmacology.

[188] G. Costabile,et al. How Well Can We Control Dyslipidemias Through Lifestyle Modifications? , 2016, Current Cardiology Reports.

[189] R. Collins,et al. Perioperative Rosuvastatin in Cardiac Surgery. , 2016, The New England journal of medicine.

[190] M. Pirinen,et al. The Contribution of GWAS Loci in Familial Dyslipidemias , 2016, PLoS genetics.

[191] C. Ballantyne,et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. , 2016, JAMA.

[192] S. Marcovina,et al. Lipoprotein (a) measurements for clinical application , 2016, Journal of Lipid Research.

[193] D. Rader,et al. Therapeutic Targets of Triglyceride Metabolism as Informed by Human Genetics. , 2016, Trends in molecular medicine.

[194] R. Hegele,et al. Combined hyperlipidemia: familial but not (usually) monogenic , 2016, Current opinion in lipidology.

[195] D. Mozaffarian. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. , 2016, European heart journal.

[196] Oluwatoyin Bamgbola,et al. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation , 2016, Therapeutic advances in endocrinology and metabolism.

[197] A. Agarwal,et al. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. , 2016, World journal of transplantation.

[198] D. Kereiakes,et al. Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome , 2016, Annals of Internal Medicine.

[199] Paul C. D. Johnson,et al. High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort , 2016, PloS one.

[200] A. Rodday,et al. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES) , 2016, Circulation.

[201] R. Nicoll,et al. The effect of statins on valve function and calcification in aortic stenosis: A meta-analysis. , 2016, Atherosclerosis.

[202] J. Manson,et al. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. , 2016, The American journal of clinical nutrition.

[203] G. Norata,et al. Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. , 2016, Current medicinal chemistry.

[204] I. Ford,et al. Long Term Safety and Efficacy of Lowering LDL Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study , 2016 .

[205] H. Brewer,et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. , 2016, European heart journal.

[206] R. Giugliano,et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. , 2016, Journal of the American College of Cardiology.

[207] L. Hartley,et al. Dietary fibre for the primary prevention of cardiovascular disease. , 2016, The Cochrane database of systematic reviews.

[208] D. Alexander,et al. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. , 2015, Journal of clinical lipidology.

[209] R. Rosenson,et al. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study , 2014, Cardiovascular Drugs and Therapy.

[210] C. Cannon,et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. , 2015, Journal of clinical lipidology.

[211] G. Helft,et al. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. , 2015, Archives of cardiovascular diseases.

[212] Peter Scarborough,et al. Cardiovascular disease in Europe--epidemiological update 2015. , 2015, European heart journal.

[213] Xueli Yang,et al. Usefulness of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as Predictors of Cardiovascular Disease in Chinese. , 2015, American Journal of Cardiology.

[214] Jennifer G. Robinson,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[215] R. Giugliano,et al. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.

[216] G. Enns,et al. A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. , 2015, The New England journal of medicine.

[217] Marco Maggioni,et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. , 2015, Journal of hepatology.

[218] N. Lundbom,et al. Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[219] J. Danesh,et al. A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease , 2016 .

[220] K. Sakamoto,et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. , 2015, Journal of the American College of Cardiology.

[221] D. Marais. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism , 2015, Current opinion in lipidology.

[222] V. Aboyans,et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. , 2015, Atherosclerosis.

[223] Elizabeth J Johnson,et al. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. , 2015, The American journal of clinical nutrition.

[224] C. Ip,et al. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. , 2015, International journal of cardiology.

[225] Milton C Weinstein,et al. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. , 2015, JAMA.

[226] G. Paragh,et al. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: A nationwide survey of 2674 individuals in Hungary. , 2015, Atherosclerosis.

[227] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[228] V. Medici,et al. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. , 2015, The American journal of clinical nutrition.

[229] R. Hegele,et al. Chylomicronaemia—current diagnosis and future therapies , 2015, Nature Reviews Endocrinology.

[230] J. Borén,et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment , 2015, European heart journal.

[231] Gretchen A. Stevens,et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. , 2015, The lancet. Diabetes & endocrinology.

[232] R. Brook,et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.

[233] Jennifer G. Robinson,et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[234] Barry J. Davis,et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials , 2015, The Lancet.

[235] T. Habuchi,et al. Characterization of Clinical and Genetic Risk Factors Associated with Dyslipidemia after Kidney Transplantation , 2015, Disease markers.

[236] Andrew E Moran,et al. Demographic and epidemiologic drivers of global cardiovascular mortality. , 2015, The New England journal of medicine.

[237] J. McMurray,et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual‐level reanalysis of CORONA and GISSI‐HF , 2015, European journal of heart failure.

[238] Marja-Riitta Taskinen,et al. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. , 2015, Atherosclerosis.

[239] Mario J. Garcia,et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. , 2015, Journal of the American College of Cardiology.

[240] B. Davis,et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials , 2015, European heart journal.

[241] M. Laakso,et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort , 2015, Diabetologia.

[242] Deepak L. Bhatt,et al. Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study , 2015, European journal of preventive cardiology.

[243] Yanyun Zhao,et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. , 2015, Journal of ethnopharmacology.

[244] Lawrence A Leiter,et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[245] D. Gaudet,et al. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome , 2015, Lipids in Health and Disease.

[246] S. Capewell,et al. Comparing Different Policy Scenarios to Reduce the Consumption of Ultra-Processed Foods in UK: Impact on Cardiovascular Disease Mortality Using a Modelling Approach , 2015, PloS one.

[247] Hynek Pikhart,et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[248] R. Hegele,et al. Hypertriglyceridemia in the genomic era: a new paradigm. , 2015, Endocrine reviews.

[249] Alex P. Reiner,et al. Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[250] E. Heintz,et al. Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries , 2015, PharmacoEconomics.

[251] V. Perkovic,et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis , 2014, Cochrane Database of Systematic Reviews.

[252] A. Ross,et al. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. , 2015, The American journal of clinical nutrition.

[253] S. Humphries,et al. Statins for children with familial hypercholesterolemia. , 2020, The Cochrane database of systematic reviews.

[254] A. Jaffe,et al. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[255] A. Jaffe,et al. Validation of a proposed novel equation for estimating LDL cholesterol. , 2014, Clinical chemistry.

[256] Vilmundur Gudnason,et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. , 2014, JAMA.

[257] P. Thompson,et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. , 2014, Journal of clinical lipidology.

[258] John Spertus,et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. , 2014, The New England journal of medicine.

[259] J. Tomassini,et al. Combination therapy in dyslipidemia: where are we now? , 2014, Atherosclerosis.

[260] J. Chardigny,et al. Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials , 2014, British Journal of Nutrition.

[261] Ž. Reiner. Resistance and intolerance to statins. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[262] T. Strandberg,et al. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. , 2014, JAMA.

[263] G. Vorobiof,et al. Insights Into Aortic Sclerosis and Its Relationship With Coronary Artery Disease , 2014, Journal of the American Heart Association.

[264] F. Kronenberg,et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. , 2014, Journal of the American College of Cardiology.

[265] J. Mckenney,et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). , 2014, The American journal of cardiology.

[266] A. Keech,et al. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study , 2014, Diabetologia.

[267] J. Borén,et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[268] Anette Varbo,et al. Triglycerides and cardiovascular disease , 2014, The Lancet.

[269] P. Ridker,et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. , 2014, Journal of the American College of Cardiology.

[270] J. Borén,et al. Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management , 2022 .

[271] Darrel P Francis,et al. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients , 2014, BMJ : British Medical Journal.

[272] A. Cicero,et al. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data , 2014, Expert opinion on drug safety.

[273] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[274] S. Bangalore,et al. Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III) , 2014, Circulation.

[275] J. Critchley,et al. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[276] Jennifer G. Robinson,et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[277] G. Watts,et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. , 2014, Journal of the American College of Cardiology.

[278] Yuejin Yang,et al. Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials , 2014, American Journal of Cardiovascular Drugs.

[279] Charles DiMaggio,et al. The cost-effectiveness of New York City's Safe Routes to School Program. , 2014, American journal of public health.

[280] Long Jiang,et al. A Meta-Analysis of Red Yeast Rice: An Effective and Relatively Safe Alternative Approach for Dyslipidemia , 2014, PloS one.

[281] Ling He,et al. Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. , 2014, Diabetes research and clinical practice.

[282] S. Pocock,et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2014, JACC. Heart failure.

[283] H. Suryapranata,et al. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. , 2014, The American journal of cardiology.

[284] N. Chalasani,et al. An assessment by the Statin Liver Safety Task Force: 2014 update. , 2014, Journal of clinical lipidology.

[285] R. Kelishadi,et al. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. , 2014, Nutrition.

[286] J. Dalen,et al. Diets to prevent coronary heart disease 1957-2013: what have we learned? , 2014, The American journal of medicine.

[287] M. Pfeffer,et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial , 2014, European heart journal.

[288] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[289] P. Barter,et al. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). , 2014, The American journal of cardiology.

[290] Stephen S. Lim,et al. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys , 2014, BMJ : British Medical Journal.

[291] P. Joshi,et al. Baseline Very Low-Density Lipoprotein Cholesterol is Associated with the Magnitude of Triglyceride Lowering on Statins, Fenofibric Acid, or Their Combination in Patients with Mixed Dyslipidemia , 2014, Journal of Cardiovascular Translational Research.

[292] R. Giugliano,et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[293] R. Brook,et al. Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials , 2014, Journal of the American Heart Association.

[294] Jbs Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3) , 2014, Heart.

[295] Simon G Thompson,et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. , 2014, Annals of internal medicine.

[296] Ben Goldacre,et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice , 2014, European journal of preventive cardiology.

[297] J. Borén,et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. , 2014, Atherosclerosis.

[298] Jennette P. Moreno,et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes , 2014, Current Atherosclerosis Reports.

[299] P. Jhund,et al. Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data , 2014, BMJ : British Medical Journal.

[300] M. Tonelli,et al. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. , 2014, Annals of internal medicine.

[301] D. Benaiges,et al. Type 1 diabetes, metabolic syndrome and cardiovascular risk. , 2014, Metabolism: clinical and experimental.

[302] J. Borén,et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. , 2014, Atherosclerosis.

[303] A. Husseini,et al. A Cost Effectiveness Analysis of Salt Reduction Policies to Reduce Coronary Heart Disease in Four Eastern Mediterranean Countries , 2014, PloS one.

[304] G. Norata,et al. Targeting PCSK9 for hypercholesterolemia. , 2014, Annual review of pharmacology and toxicology.

[305] S. Loke,et al. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review * , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[306] A. Khera,et al. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.

[307] I. Ford,et al. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study , 2013, European heart journal.

[308] Vijay Nambi,et al. The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations , 2014, Current Atherosclerosis Reports.

[309] Desmond E. Williams,et al. Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[310] B. Nordestgaard,et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. , 2014, Journal of clinical lipidology.

[311] I. Thompson,et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. , 2014, Journal of the National Cancer Institute.

[312] R. Malekzadeh,et al. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. , 2013, The Cochrane database of systematic reviews.

[313] K. Bennett,et al. Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008 , 2013, BMC Public Health.

[314] F. Sofi,et al. Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score , 2013, Public Health Nutrition.

[315] D. Droste,et al. A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial , 2013, Nutrition Journal.

[316] K. Bennett,et al. Explaining the Decline in Coronary Heart Disease Mortality in Portugal Between 1995 and 2008 , 2013, Circulation. Cardiovascular quality and outcomes.

[317] R. Herings,et al. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010. , 2013, European heart journal.

[318] A. Lichtenstein,et al. Dietary Cholesterol and Plasma Lipoprotein Profiles: Randomized Controlled Trials , 2013, Current Nutrition Reports.

[319] Wolfgang Koenig,et al. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. , 2013, International journal of cardiology.

[320] Peter Scarborough,et al. Cardiovascular disease in Europe: epidemiological update. , 2014, European heart journal.

[321] Tanya M. Teslovich,et al. Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[322] R. Christensen,et al. Whole grain and body weight changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. , 2013, The American journal of clinical nutrition.

[323] A. Demchuk,et al. Reduction in Early Stroke Risk in Carotid Stenosis With Transient Ischemic Attack Associated With Statin Treatment , 2013, Stroke.

[324] Ž. Reiner. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[325] M. Banach,et al. Acute coronary syndromes in patients with chronic kidney disease. , 2013, Current vascular pharmacology.

[326] P. Joshi,et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. , 2013, Journal of the American College of Cardiology.

[327] Catherine Boileau,et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease , 2013, European heart journal.

[328] Michael R. Jones,et al. Role of Colesevelam in Combination Lipid-Lowering Therapy , 2013, American Journal of Cardiovascular Drugs.

[329] Chi Pang Wen,et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[330] O. Wiklund,et al. Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy , 2013, Current Cardiology Reports.

[331] Jeroen J. Bax,et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[332] Huseyin Naci,et al. Comparative Tolerability and Harms of Individual Statins: A Study-Level Network Meta-Analysis of 246 955 Participants From 135 Randomized, Controlled Trials , 2013, Circulation. Cardiovascular quality and outcomes.

[333] Z. Kabir,et al. Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland , 2013, BMJ Open.

[334] B. Nordestgaard,et al. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. , 2013, European heart journal.

[335] A. Levin,et al. Practice Guideline , 2020, Encyclopedia of Behavioral Medicine.

[336] M. Pencina,et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. , 2013, Pharmacological research.

[337] R. Hegele,et al. Apolipoprotein C-III: going back to the future for a lipid drug target. , 2013, Circulation research.

[338] Richard G. Lee,et al. Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans , 2013, Circulation research.

[339] Francisco A H Fonseca,et al. Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. , 2013, Life sciences.

[340] Dolores Corella,et al. Primary prevention of cardiovascular disease with a Mediterranean diet. , 2013, The New England journal of medicine.

[341] D. Mozaffarian,et al. Plasma Phospholipid Long-Chain-3 Fatty Acids and Total and Cause-Specific Mortality in Older Adults A Cohort Study , 2013 .

[342] B. Nordestgaard,et al. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. , 2013, Journal of the American College of Cardiology.

[343] M. Banach,et al. The risk of atherosclerosis in patients with chronic kidney disease , 2013, International Urology and Nephrology.

[344] J. Guyton,et al. Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy , 2013, The Annals of pharmacotherapy.

[345] H. Naci,et al. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials , 2013, European journal of preventive cardiology.

[346] B. Nordestgaard,et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[347] D. Gaudet,et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[348] O. Franco,et al. Population-level changes to promote cardiovascular health , 2012, European journal of preventive cardiology.

[349] J. Kastelein,et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. , 2012, Journal of the American College of Cardiology.

[350] Karine Tremblay,et al. Efficacy and long term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open label trial , 2012, Gene Therapy.

[351] MartaPereira,et al. Explaining the Decline in Coronary Heart Disease Mortality in Portugal Between 1995 and 2008 , 2013 .

[352] G. Bray,et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[353] O. Franco,et al. [Population-level changes to promote cardiovascular health]. , 2013, Vnitrni lekarstvi.

[354] N. Sattar,et al. Revisiting the links between glycaemia, diabetes and cardiovascular disease , 2013, Diabetologia.

[355] Shah Ebrahim,et al. [European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)]. , 2013, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[356] K. Williams,et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. , 2012, Journal of the American College of Cardiology.

[357] S. Yusuf,et al. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. , 2012, Atherosclerosis.

[358] Markus Abt,et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[359] A. Keech,et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. , 2012, Journal of the American College of Cardiology.

[360] T. Okamura,et al. A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. , 2012, Atherosclerosis.

[361] W. S. Yancy,et al. Systematic review and meta‐analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors , 2012, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[362] J. Gallacher,et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[363] C. Ballantyne,et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). , 2012, The American journal of cardiology.

[364] C. Guerriero,et al. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop , 2012, The European Journal of Health Economics.

[365] J. Després,et al. Body Fat Distribution and Risk of Cardiovascular Disease: An Update , 2012, Circulation.

[366] J. McMurray,et al. Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials , 2012, PLoS medicine.

[367] D. Goff,et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. , 2012, JAMA.

[368] Giel Nijpels,et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. , 2012, JAMA.

[369] P. Ridker,et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. , 2012, JAMA.

[370] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[371] John Spertus,et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[372] S. Linnebur,et al. FDA drug safety communications: a narrative review and clinical considerations for older adults. , 2012, The American journal of geriatric pharmacotherapy.

[373] L. Riella,et al. Dyslipidemia and Its Therapeutic Challenges in Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[374] W. Weintraub,et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. , 2012, Atherosclerosis.

[375] W. Kostis,et al. Statin Therapy and the Risk of Intracerebral Hemorrhage: A Meta-Analysis of 31 Randomized Controlled Trials , 2012, Stroke.

[376] T. Vos,et al. Which Interventions Offer Best Value for Money in Primary Prevention of Cardiovascular Disease? , 2012, PloS one.

[377] T. Dayspring,et al. Ezetimibe therapy: mechanism of action and clinical update , 2012, Vascular health and risk management.

[378] Shah Ebrahim,et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[379] W. Kraus,et al. Exercise effects on lipids in persons with varying dietary patterns-does diet matter if they exercise? Responses in Studies of a Targeted Risk Reduction Intervention through Defined Exercise I. , 2012, American heart journal.

[380] B. Lindkvist,et al. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[381] J. Gallacher,et al. Lipid-related markers and cardiovascular disease prediction. , 2012, JAMA.

[382] Lu Gao,et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data , 2012, The Lancet.

[383] P. Ridker,et al. Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2012, Circulation. Cardiovascular genetics.

[384] A. Hofman,et al. Evaluation of Newer Risk Markers for Coronary Heart Disease Risk Classification , 2012, Annals of Internal Medicine.

[385] A. Rosengren. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? , 2012, European heart journal.

[386] Evangelos Kalaitzakis,et al. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. , 2012, Journal of hepatology.

[387] J. Schold,et al. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[388] Raimund Erbel,et al. [2011 ESC guidelines on the diagnosis and treatment of peripheral artery diseases]. , 2012, Revue medicale de Liege.

[389] Avis J. Thomas,et al. Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.

[390] John Simes,et al. Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy , 2012, PloS one.

[391] P. Cochat,et al. Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[392] P. Toth. Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis , 2012 .

[393] T. A. Jacobson,et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. , 2012, Journal of clinical lipidology.

[394] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[395] J. Bryant,et al. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. , 2011, Health technology assessment.

[396] Eric E. Smith,et al. Statins and Intracerebral Hemorrhage: Collaborative Systematic Review and Meta-Analysis , 2011, Circulation.

[397] T. A. Jacobson,et al. Effects of Eicosapentaenoic Acid Versus Docosahexaenoic Acid on Serum Lipids: A Systematic Review and Meta-Analysis , 2011, Current atherosclerosis reports.

[398] R. Hart,et al. Statins for women with polycystic ovary syndrome not actively trying to conceive. , 2011, The Cochrane database of systematic reviews.

[399] C. Ballantyne,et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). , 2011, The American journal of cardiology.

[400] G. Baio,et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. , 2011, Atherosclerosis.

[401] T. Vos,et al. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity , 2011, International Journal of Obesity.

[402] J. Saver,et al. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. , 2011, Atherosclerosis.

[403] S. Achenbach,et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. , 2011, European heart journal.

[404] A. Briggs,et al. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study , 2011, BMJ : British Medical Journal.

[405] E. Colman,et al. Weighing the benefits of high-dose simvastatin against the risk of myopathy. , 2011, The New England journal of medicine.

[406] K. Musa-Veloso,et al. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[407] P. Kolh,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[408] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.

[409] D. Mozaffarian,et al. Components of a Cardioprotective Diet: New Insights , 2011, Circulation.

[410] M. Landray,et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[411] M. Briel,et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. , 2011, European heart journal.

[412] B. Nordestgaard,et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis , 2011 .

[413] B. Nordestgaard,et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. , 2011, Current vascular pharmacology.

[414] J. Borén,et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[415] Paul M Ridker,et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). , 2011, Journal of the American College of Cardiology.

[416] C. Cannon,et al. Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies , 2011, Circulation.

[417] Marie T. Brown,et al. Medication adherence: WHO cares? , 2011, Mayo Clinic proceedings.

[418] P. Macfarlane,et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials , 2011, BMJ : British Medical Journal.

[419] D. Panagiotakos,et al. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. , 2011, Journal of the American College of Cardiology.

[420] R. Shamburek,et al. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. , 2011, Clinical chemistry.

[421] P. Austin,et al. Statins and renovascular disease in the elderly: a population-based cohort study. , 2011, European heart journal.

[422] W. Ghali,et al. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies , 2011, BMJ : British Medical Journal.

[423] P. Touboul,et al. Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis , 2011, Journal of cardiovascular pharmacology.

[424] G. Guyatt,et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. , 2011, QJM : monthly journal of the Association of Physicians.

[425] A. Alwan. Global status report on noncommunicable diseases 2010. , 2011 .

[426] Ian Graham,et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[427] B. Nordestgaard,et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. , 2011, Current vascular pharmacology.

[428] Jiayin Yang,et al. Higher Tacrolimus Blood Concentration Is Related to Hyperlipidemia in Living Donor Liver Transplantation Recipients , 2011, Digestive Diseases and Sciences.

[429] J. Shepherd,et al. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. , 2011, Health technology assessment.

[430] M. Taskinen,et al. [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[431] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[432] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[433] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[434] V. Gudnason,et al. Analysing the Large Decline in Coronary Heart Disease Mortality in the Icelandic Population Aged 25-74 between the Years 1981 and 2006 , 2010, PloS one.

[435] A. Cass. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.

[436] J. Borén,et al. Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[437] R. Chapman,et al. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[438] Helmuth Steinmetz,et al. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). , 2010, European heart journal.

[439] R. Hoogenveen,et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD , 2010, Thorax.

[440] Ralph D'Agostino,et al. Risk Prediction in Cardiovascular Medicine Cardiovascular Risk-Estimation Systems in Primary Prevention Do They Differ ? Do They Make a Difference ? Can We See the Future ? , 2010 .

[441] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.

[442] P. Passmore,et al. Statins for the treatment of dementia , 2010, Alzheimer's & Dementia.

[443] J Wouter Jukema,et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.

[444] J. Danesh,et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. , 2010, Lancet.

[445] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[446] P. Giral,et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. , 2010, Pharmacology & therapeutics.

[447] P. Barter,et al. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database , 2010, Journal of Lipid Research.

[448] J. Graaf,et al. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias , 2010, Nature Reviews Endocrinology.

[449] R. Shamburek,et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. , 2010, Clinical chemistry.

[450] R. Arora,et al. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials. , 2010, International journal of cardiology.

[451] J. Danesh,et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[452] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.

[453] Y. Jang,et al. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. , 2010, JACC. Cardiovascular interventions.

[454] D. Mozaffarian,et al. Effects on Coronary Heart Disease of Increasing Polyunsaturated Fat in Place of Saturated Fat: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010, PLoS medicine.

[455] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[456] T. Frieden. A framework for public health action: the health impact pyramid. , 2010, American journal of public health.

[457] S. Yusuf,et al. Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes , 2010, Circulation.

[458] K. Teo,et al. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[459] B. Gersh. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002 , 2010 .

[460] T. Pedersen. Pleiotropic Effects of Statins , 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[461] R. Collins,et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.

[462] P. Hardt,et al. Severe hypertriglyceridemia and pancreatitis: presentation and management , 2009, Current opinion in lipidology.

[463] A. Colombo,et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. , 2009, Journal of the American College of Cardiology.

[464] Jeroen J. Bax,et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. , 2009, The New England journal of medicine.

[465] P. Whincup,et al. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[466] I. Graham,et al. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. , 2009, Journal of the American College of Cardiology.

[467] G. Costabile,et al. Effects of a Plant-Based High-Carbohydrate/High-Fiber Diet Versus High–Monounsaturated Fat/Low-Carbohydrate Diet on Postprandial Lipids in Type 2 Diabetic Patients , 2009, Diabetes Care.

[468] V. Pasceri,et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. , 2009, Journal of the American College of Cardiology.

[469] Stephen Kaptoge,et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[470] Shahrul Mt-Isa,et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.

[471] P. Ridker. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT) , 2009, Journal of thrombosis and haemostasis : JTH.

[472] J Shepherd,et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.

[473] Børge G Nordestgaard,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[474] J. Benner,et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[475] A. Keech,et al. Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate , 2009, Arteriosclerosis, Thrombosis and Vascular Biology.

[476] Mark Sculpher,et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[477] M. Laakso,et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial , 2009, The Lancet.

[478] D. Mozaffarian,et al. Health effects of trans-fatty acids: experimental and observational evidence , 2009, European Journal of Clinical Nutrition.

[479] P. Amarenco,et al. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention , 2009, The Lancet Neurology.

[480] S. Paisley,et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials , 2009, Journal of internal medicine.

[481] Simon Capewell,et al. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. , 2009, European heart journal.

[482] M. Molinari,et al. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[483] Wei Zhang,et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. , 2009, The Journal of clinical investigation.

[484] Sonia S Anand,et al. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. , 2009, Archives of internal medicine.

[485] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.

[486] Gert Mayer,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[487] G. Boysen,et al. European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[488] J. Fildes,et al. The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin , 2009, Transplantation.

[489] G. Hitman,et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). , 2009, Clinical chemistry.

[490] D. Mozaffarian,et al. Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention , 2009, Circulation.

[491] J. Kastelein,et al. Combination statin–fibrate therapy: safety aspects , 2009, Diabetes, obesity & metabolism.

[492] Jennifer G. Robinson,et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. , 2009, Journal of the American College of Cardiology.

[493] C. N. Bairey Merz,et al. Contraceptive hormone use and cardiovascular disease. , 2009, Journal of the American College of Cardiology.

[494] A. Keech,et al. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome , 2008, Diabetes Care.

[495] David W. Johnson,et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, The Cochrane database of systematic reviews.

[496] P. Passmore,et al. Statins for the prevention of dementia. , 2009, The Cochrane database of systematic reviews.

[497] N. Toma. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis , 2009 .

[498] G. Kelley,et al. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. , 2009, Preventive medicine.

[499] M. Pratt,et al. Cost effectiveness of community-based physical activity interventions. , 2008, American journal of preventive medicine.

[500] Edward J. Mills,et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.

[501] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[502] Børge G Nordestgaard,et al. Genetically elevated C-reactive protein and ischemic vascular disease. , 2008, The New England journal of medicine.

[503] Gissi-Hf Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[504] Gissi-Hf Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[505] 淳一佐々木. Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .

[506] R. Giacco,et al. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[507] J. Chambers,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[508] G. Feuchtner,et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). , 2008, The American journal of cardiology.

[509] Samia Mora,et al. Fasting Compared With Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events , 2008, Circulation.

[510] E. Tuzcu,et al. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. , 2008, Journal of the American College of Cardiology.

[511] H. Meier‐Kriesche,et al. Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[512] D. Capuzzi,et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.

[513] O. Faergeman,et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial , 2008, The Lancet.

[514] Børge G Nordestgaard,et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. , 2008, JAMA.

[515] L. Niskanen,et al. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men , 2008, Current medical research and opinion.

[516] G. Warnick,et al. Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B. , 2008, Clinical chemistry.

[517] V. Kamanna,et al. Mechanism of action of niacin. , 2008, The American journal of cardiology.

[518] C. la Vecchia,et al. Non-pharmacological control of plasma cholesterol levels. , 2008, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[519] Cholesterol Treatment Trialists' Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[520] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.

[521] J. Robson,et al. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease , 2007, Heart.

[522] R. Karas,et al. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. , 2008, The American journal of cardiology.

[523] L. Tavazzi,et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[524] R. Collins,et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.

[525] L. Segal,et al. Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. , 2007, Health promotion international.

[526] A. Jánosi,et al. Rosuvastatin in older patients with systolic heart failure. , 2007, The New England journal of medicine.

[527] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[528] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.

[529] J. Price,et al. Lipid-lowering for peripheral arterial disease of the lower limb. , 2007, The Cochrane database of systematic reviews.

[530] J. Borén,et al. Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[531] Christopher P Cannon,et al. Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[532] Kieran Sweeney,et al. Preventive health care in elderly people needs rethinking , 2007, BMJ : British Medical Journal.

[533] S. Ward,et al. A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[534] M. Pfeffer,et al. Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease , 2007, Circulation.

[535] J. Mckenney,et al. Safety considerations with fibrate therapy. , 2007, The American journal of cardiology.

[536] D. Waters,et al. Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study , 2007, Circulation.

[537] Richard E Gregg,et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[538] B. Jönsson,et al. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. , 2006, European heart journal.

[539] R. Agarwal. Effects of statins on renal function. , 2006, Mayo Clinic proceedings.

[540] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[541] J. Golledge,et al. Atvb in Focus Abdominal Aortic Aneurysms: Pathophysiological Mechanisms and Clinical Implications Abdominal Aortic Aneurysm Pathogenesis and Implications for Management , 2022 .

[542] Andrew Briggs,et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people , 2006, BMJ : British Medical Journal.

[543] J. Lau,et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. , 2006, Atherosclerosis.

[544] C. Del Mar,et al. Exercise for overweight or obesity. , 2006, The Cochrane database of systematic reviews.

[545] G. Hamilton,et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? , 2006, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[546] J. Cristol,et al. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? , 2006, Transplantation proceedings.

[547] M. Hennerici,et al. High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[548] Christopher P Cannon,et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[549] M. Sabatine,et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. , 2006, Journal of the American College of Cardiology.

[550] J. Danesh,et al. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature‐based meta‐analysis of prospective studies , 2006, Journal of internal medicine.

[551] Alicja R Rudnicka,et al. Statin safety: a systematic review. , 2006, The American journal of cardiology.

[552] John A. Clark,et al. Statin safety: an appraisal from the adverse event reporting system. , 2006, The American journal of cardiology.

[553] Julian P T Higgins,et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review , 2006, BMJ : British Medical Journal.

[554] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[555] C. Hollenbeck,et al. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. , 2006, The Journal of clinical endocrinology and metabolism.

[556] Matthias Briel,et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[557] B. Caramelli,et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial , 2006 .

[558] J. Tsai,et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. , 2006, The American journal of cardiology.

[559] W. März,et al. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta–analysis , 2006, Clinical Research in Cardiology.

[560] E. Bruckert,et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[561] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.

[562] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[563] N. Cook,et al. Association of Common CRP Gene Variants with CRP Levels and Cardiovascular Events , 2005, Annals of human genetics.

[564] E. Braunwald,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.

[565] Ž. Reiner,et al. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. , 2005, The American journal of cardiology.

[566] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[567] J. Rees. Prevalence , 2005, BMJ : British Medical Journal.

[568] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[569] R. Prescott,et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[570] F. Mach,et al. Statins Reduce Interleukin-6–Induced C-Reactive Protein in Human Hepatocytes: New Evidence for Direct Antiinflammatory Effects of Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[571] N. Chalasani,et al. Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes , 2005, The American journal of the medical sciences.

[572] G. Miller,et al. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.

[573] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[574] A. Hoes,et al. [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[575] Ž. Reiner,et al. Effects of Rice Policosanol on Serum Lipoproteins, Homocysteine, Fibrinogen and C-Reactive Protein in Hypercholesterolaemic Patients , 2005, Clinical drug investigation.

[576] Y. Jang,et al. Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[577] Richard Platt,et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[578] M. Davidson. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance , 2004, Expert opinion on drug safety.

[579] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[580] W. Sasiela,et al. High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial , 2004, Circulation.

[581] J. Sidaway,et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. , 2004, Journal of the American Society of Nephrology : JASN.

[582] 曲东锋. Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .

[583] J. Davignon. Beneficial Cardiovascular Pleiotropic Effects of Statins , 2004, Circulation.

[584] Joe Kesterson,et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[585] Vilmundur Gudnason,et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[586] M. Koschinsky,et al. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. , 2003, Clinical chemistry.

[587] P. Greenland,et al. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. , 2003, Archives of internal medicine.

[588] T. Fukui,et al. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. , 2003, Preventive medicine.

[589] Mary Cushman,et al. Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[590] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.

[591] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[592] A. J. Swerdlow,et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes , 2003, Diabetologia.

[593] R. Mensink,et al. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. , 2003, The American journal of clinical nutrition.

[594] A. Tonkin,et al. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. , 2003, American heart journal.

[595] A. Louheranta,et al. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. , 2003, Atherosclerosis.

[596] T. Meade,et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial , 2002, BMJ : British Medical Journal.

[597] W. Kraus,et al. Effects of the amount and intensity of exercise on plasma lipoproteins. , 2002, The New England journal of medicine.

[598] J. Faith,et al. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. , 2002, Human reproduction.

[599] C. Ballantyne,et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients DOI 10.1194/jlr.M100392-JLR200 , 2002, Journal of Lipid Research.

[600] L. Tavazzi,et al. Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione , 2002 .

[601] Nader Rifai,et al. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. , 2002, Clinical chemistry.

[602] J. Hendriks,et al. Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[603] M. Lauer,et al. Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis , 2001, Circulation.

[604] Paul M. Ridker,et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.

[605] Michael F. Oliver,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[606] J. Manson,et al. Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. , 2001, The American journal of clinical nutrition.

[607] G. Riccardi,et al. Effect of acute exogenous hyperinsulinaemia on very low density lipoprotein subfraction composition in normal subjects , 2001, European journal of clinical investigation.

[608] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[609] J. Larosa,et al. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[610] E. Rimm,et al. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors , 1999, BMJ.

[611] L. Appel,et al. Effect of dietary patterns on ambulatory blood pressure : results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. , 1999, Hypertension.

[612] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[613] J. Illnait,et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors , 1999, Clinical pharmacology and therapeutics.

[614] P. Kris-Etherton,et al. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. , 1999, The American journal of clinical nutrition.

[615] Jean-Louis Martin,et al. Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study , 1999 .

[616] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[617] B. Rosner,et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. , 1999, The American journal of clinical nutrition.

[618] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[619] Ian Graham,et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. , 1998, European heart journal.

[620] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.

[621] N. Santanello,et al. Cholesterol reduction yields clinical benefit: impact of statin trials. , 1998, Circulation.

[622] O. Faergeman,et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[623] O. Faergeman,et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. , 1997, Journal of cardiac failure.

[624] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[625] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[626] N. Santanello,et al. Cholesterol reduction yields clinical benefit. A new look at old data. , 1995, Circulation.

[627] L. Wilkins. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. , 1992, Circulation.

[628] A. Dattilo,et al. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[629] The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. , 1992, Archives of internal medicine.

[630] Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. , 1991, BMJ.

[631] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[632] D. Gordon,et al. Lipid Research Clinics Coronary Primary Prevention Trial , 1986 .

[633] L. D. de Villiers,et al. Prevalence of familial hypercholesterolemia. , 1986, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[634] C. E. Becker. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[635] The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.

[636] Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial. , 1983, Journal of chronic diseases.

[637] C. Dolea,et al. World Health Organization , 1949, International Organization.

[638] Thomas Francis,et al. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS , 1930, The Journal of experimental medicine.